Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Redeye Investor Forum (May 2026)
30 slides from Alzecure Pharma Ab's conference presentation, May 21, 2026
Slide 1: Developing therapies for Alzheimer's & pain
May 21, 2026 Developing therapies for Alzheimer’s & pain
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements regarding the Company’s intentions, assessments, or expectations in respect of the Company’s future results, financial position, liquidity, development, prospects, expected growth, strategies and possibilities as well as the market wit
Slide 3: AlzeCure Pharma in brief
AlzeCure Pharma in brief
Slide 4: AlzeCure Pharma – In brief
Introduction AlzeCure Pharma – In brief • Working in Alzheimer’s Disease (AD) & Pain – high unmet medical need & multi-billion sales Professor Jan Lundberg – Board member Former global head of R&D at Eli Lilly & global head potential of research at AstraZeneca joining & investing • Spin-out from Ast
Slide 5: Our Business Model
Introduction Our Business Model Are a Research & Development company Research & develop through early clinical phase and then to out-license or partner on our projects Gain incomes through: Upfront Milestone Royalties on payments payments sold products 5
Slide 6: A pipeline of Small-Molecule Programs
Introduction A pipeline of Small-Molecule Programs Multiple candidates increase chance of success Research Preclinical Phase I Phase II Phase III Platform Candidate Target Indication phase phase Alzheimer’s Disease, Positive allosteric TBI - Traumatic brain Positive read-out Neuro ACD856 modulator (
Slide 7: Two Alzheimer's platforms - 1st-in-class properties & potential game-changers
Two Alzheimer’s platforms - 1st-in-class properties & potential game-changers MEETING NEEDS OF AD PATIENTS – ADRESSING SHORT TERM NEEDS WITH LONG-TERM BENEFITS Preventive Disease-modifying therapy Symptomatic & pot. Disease-modifying therapy Alzstatin® NeuroRestore® Gamma-secretase modulator Trk-PAM
Slide 8: NeuroRestore – Trk-PAM improving neuronal function & cognition in Alzheimer's disease
NeuroRestore® – Trk-PAM improving neuronal function & cognition in Alzheimer’s disease
Slide 9: The importance of BDNF & NGF signaling in Alzheimer's
NeuroRestore® – positive allosteric modulator of Trk-receptors The importance of BDNF & NGF signaling in Alzheimer’s • The neurotrophins Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) bind to their respective receptors, TrkB and TrkA and are key for brain health and cognition
Slide 10: Mechanism of Action of NeuroRestore ACD856
NeuroRestore® – positive allosteric modulator of Trk-receptors Mechanism of Action of NeuroRestore ACD856 TrkA/B • ACD856 is a novel oral small molecule positive modulator of Trk-receptors enhancing the signaling of neurotrophins such as NGF & BDNF NGF/ BDNF • The enhanced signaling leads to immedia
Slide 11: NeuroRestore – Cognitive Enhancer Improving Learning & Memory Ability
NeuroRestore® – positive allosteric modulator of Trk-receptors NeuroRestore® – Cognitive Enhancer Improving Learning & Memory Ability Stages of memory formation LEARN STORE REMEMBER Transforming information Maintaining the encoded Re-accessing the information into a form that can be stored in inform
Slide 12: Phase I Demonstrated Safety, Tolerability & Target Engagement
NeuroRestore® – positive allosteric modulator of Trk-receptors Phase I Demonstrated Safety, Tolerability & Target Engagement • ACD856 is safe & well tolerated − Single and repeated dosing with ACD856 did not result in any serious adverse events in healthy volunteers at the tested dose levels • ACD85
Slide 13: Grant financed Phase IIa study to investigate safety & efficacy of ACD856
NeuroRestore® – positive allosteric modulator of Trk-receptors Grant financed Phase IIa study to investigate the safety & efficacy of ACD856 in Alzheimer’s disease https://www.alzecurepharma.se/en/alzecure-receives-eu-grant-for-phase-2-clinical-trial-of-neurorestore-acd856-for-alzheimers-disease/ 13
Slide 14: Alzstatin – gamma-secretase modulator targeting amyloid production
Alzstatin® – gamma-secretase modulator targeting amyloid production for prevention and treatment of Alzheimer’s disease
Slide 15: The Alzheimer's Brain and its Destruction by Toxic Protein
Alzstatin ® – gamma-secretase modulator The Alzheimer’s Brain and its Destruction by Toxic Protein The Amyloid Cascade Toxic protein formations, built up of Aβ42, are harming and destroying brain structures AlzeCure’s GSM1 Alzstatin® reduces Aβ42 to diminish the build-up of toxic fragments & plaque
Slide 16: Alzstatin – Potent Reduction of Toxic Aβ42 & Increasing Protective Aβ37 & Aβ38
Alzstatin ® – gamma-secretase modulator Alzstatin® – Potent Reduction of Toxic Aβ42 & Increasing Protective Aβ37 & Aβ38 Alzstatin® potently reduces the amount of Alzstatin® reduces toxic Aβ42 and Aβ40, while toxic brain Aβ42 in animals increasing protective Aβ38 and Aβ37 peptides Αβ42 150 3000 % of
Slide 17: New preclinical data shows Induced Plaque Regression
Alzstatin ® – gamma-secretase modulator New preclinical data shows Induced Plaque Regression Two-photon-study preclinical study in APP/PS1 mice Vehicle AZ4126 Day 0 Day 28 Day 0 Day 28 Distribution of plaque growth & Plaque appearance or regression disappearance 28-day GSM treatment Reduces amyloid
Slide 18: Multiple Potential Treatment Populations for Alzstatin
Alzstatin ® – gamma-secretase modulator Multiple Potential Treatment Populations for Alzstatin – Maintenance, Combination & Preventive Therapy Maintenance therapy - in patients with established Alzheimer’s disease • Treatment after initial plaque clearance by monoclonal antibody treatment (as initia
Slide 19: Early clinical Proof-of-Mechanism – Already in Phase I
Alzstatin ® – gamma-secretase modulator Early clinical Proof-of-Mechanism – Already in Phase I • Phase I will demonstrate proof of mechanism (PoM) and central target engagement • SAD/MAD studies conducted in healthy volunteers + Alzheimer’s patients • Evaluation of safety and tolerability after sing
Slide 20: Interim phase II data on Roche GSM expected in 2026
Alzstatin ® – gamma-secretase modulator Interim phase II data on Roche GSM expected in 2026 The data is validating & increasing interest in Alzstatin® 20
Slide 21: PainLess – targeting unmet medical needs within pain
PainLess – targeting unmet medical needs within pain
Slide 22: Introduction to our platforms PAINLESS
PainLess Introduction to our platforms PAINLESS Osteoarthritis & severe pain Neuropathic pain conditions > 300 million patients > 600 million patients Project: ACD137 Project: ACD440 Negative allosteric modulator of TrkA- Topical TRPV1 antagonist in clinical receptors in research phase Phase II 22
Slide 23: ACD137 – Non-Opioid Treatment of Osteoarthritis & Severe Pain
ACD137 - Negative allosteric modulator of TrkA-receptors ACD137 – Non-Opioid Treatment of Osteoarthritis & Severe Pain Attractive E.g., osteoarthritis in patients who have experienced insufficient pain relief from 1st line target population standard of care or unacceptable side effects Clinical Mech
Slide 24: ACD137 positions AlzeCure in next-generation TrkA pain therapies
ACD137 - Negative allosteric modulator of TrkA-receptors ACD137 positions AlzeCure in next-generation TrkA pain therapies Compound Company TrkA (nM) TrkB (nM) TrkA vs TrkB Status Indication OA1 & ACD137 AlzeCure 0.87 26 400 30,300 Preclin other pain conditions Cmpd #10 Array Bio. OA 0.038 210 5,500
Slide 25: ACD440 – Novel TRPV1 antagonist in clinical phase for neuropathic pain
ACD440 – a TRPV1 antagonist ACD440 – Novel TRPV1 antagonist in clinical phase for neuropathic pain Project overview Emanates from Big Pharma TRPV1 – Optimized for local delivery Positive clinical trial results in phase Ib & IIa • Approximately 20M USD already • The vanilloid receptor subtype 1 • Dev
Slide 26: Positive phase IIa results for First-in-Class ACD440
ACD440 – a TRPV1 antagonist Positive phase IIa results for First-in-Class ACD440 • Demonstrate Positive Proof-of-Mechanism (PoM) results in patients with chronic peripheral neuropathic pain in a placebo cross-over trial • The patients have had chronic pain for many years & were on concomitant medica
Slide 27: Strong regulatory momentum in US and EU
ACD440 – a TRPV1 antagonist Strong regulatory momentum in US and EU Granted orphan drug designation (US & EU) Erythromelalgia • FDA granted Orphan Drug Designation (ODD) for • Erythromelalgia is a rare chronic painful disorder – erythromelalgia ”Burning Feet Syndrome” existing in children & adults •
Slide 28: Summary
Summary
Slide 29: Key Investment Highlights in AlzeCure
Key Investment Highlights in AlzeCure Targeting areas of significant unmet medical needs m Strong team with extensive experience and track record – from idea to clinic Platforms with first-in-class properties and potential game-changers Parallel investments in several candidates and potent follow-up
Slide 30: Karolinska Institutet Novum Science Park
Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN Martin.jonsson@alzecurepharma.com www.alzecurepharma.com